logo-loader
HealthPharma & Biotech
AstraZeneca

AstraZeneca gets US regulatory green light for slow-release diabetes drug

Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control

green traffic light
America’s Food & Drug Administration gave the nod for the once-a-day treatment after the Anglo-Swedish drugs giant successfully carried out two phase III clinical trials

AstraZeneca PLC (LON:AZN) has received the US regulatory green light for a slow-release version of its type-2 diabetes treatment.

Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control.

America’s Food & Drug Administration gave the nod for the once-a-day treatment after the Anglo-Swedish drugs giant successfully carried out two phase III clinical trials.

Quick facts: AstraZeneca

Price: £72.56

Market: LSE
Market Cap: £95.19 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zena Pay looks to help cannabis industry navigate the...

Fig House communication’s Dave Carter joined Steve Darling from Proactive Vancouver to discuss Zena Pay. They provide software solutions that specialize in payment, plant tracking, cannabis business management software, supply chain management, compliance management and government auditing...

1 day, 3 hours ago

2 min read